title: Efficacy of an ondansetron orally disintegrating tablet: a novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the Ondansetron Orally Disintegrating Tablet in Radiotherapy Treatment.
abstract: A significant number of patients who are receiving radiotherapy experience the distressing side effects of emesis and nausea. Although prophylactic antiemetics are often given to patients who are receiving single-fraction, high-dose radiotherapy to the abdomen, a survey has revealed that antiemetic prophylaxis is not routinely offered to those receiving fractionated radiotherapy. Hence there is a need for an effective treatment of emesis for use in this group of patients. Ondansetron is an effective and well-tolerated antiemetic, which is used for the prevention of both chemotherapy and radiotherapy-induced emesis and nausea. This agent has been developed as a novel freeze-dried oral formulation. Ondansetron orally disintegrating tablets (ondODT) disperse rapidly when placed on the tongue. As the tablet does not need to be swallowed with water, it is a particularly useful formulation for patients who have difficulty with swallowing or who do not feel able to drink. This study was undertaken to investigate the efficacy of ondODT in the treatment of established emesis and nausea induced by radiotherapy. Two doses of ondODT, 8 mg and 16 mg, were compared with placebo in patients who developed emesis and/or moderate/severe nausea after receiving fractionated radiotherapy to sites located between the thorax and the pelvis. The study showed that ondODT was clinically superior to placebo in treating emesis and nausea successfully over a 12-hour period after taking the medication. There were no statistically significant differences between the two doses of ondODT. In the 2 hours after taking the study medication, patients who received ondODT (8 mg and 16 mg) had significantly fewer emetic episodes compared with those who received placebo. They also experienced significantly less nausea. In conclusion, ondODT 8 mg is effective in the treatment of radiotherapy-induced emesis and nausea and provides an effective alternative to the conventional ondansetron tablet.
authors.affiliation: Hospital Henri Mondor, Creteil, France.
authors.forename: J P
authors.initials: JP
authors.lastname: LeBourgeois
authors.forename: C J
authors.initials: CJ
authors.lastname: McKenna
authors.forename: B
authors.initials: B
authors.lastname: Coster
authors.forename: P
authors.initials: P
authors.lastname: Feyer
authors.forename: L
authors.initials: L
authors.lastname: Franzén
authors.forename: L
authors.initials: L
authors.lastname: Goedhals
authors.forename: Z
authors.initials: Z
authors.lastname: Marzecki
authors.forename: L
authors.initials: L
authors.lastname: Souhami
authors.forename: A
authors.initials: A
authors.lastname: Stewart
authors.forename: F
authors.initials: F
authors.lastname: Tønnessen
authors.forename: C
authors.initials: C
authors.lastname: Haigh
authors.forename: T
authors.initials: T
authors.lastname: Mitchell
authors.forename: J R
authors.initials: JR
authors.lastname: Wilkinson
authors.forename: E
authors.initials: E
authors.lastname: Graham
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000932:Antiemetics / Q000008:administration & dosage* / Q000009:adverse effects; D019583:Dose Fractionation, Radiation; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000188:drug therapy* / Q000209:etiology; D017294:Ondansetron / Q000008:administration & dosage* / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects*; D012702:Serotonin Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D013607:Tablets; D014839:Vomiting / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000932:Antiemetics; D012702:Serotonin Antagonists; D013607:Tablets; D017294:Ondansetron